Sirolimus-Eluting Balloon in Femoropopliteal Disease

Drug-eluting balloons (DEB) with paclitaxel have shown efficacy and safety in the treatment of femoropopliteal disease. Sirolimus-eluting balloons (DEB S) are currently being introduced.

This new drug acts during the cellular resting phase (G0) and is considered potentially more effective than paclitaxel, which is a cytostatic drug. However, there is no conclusive evidence in this regard yet.

The SELUTION SFA study included 134 patients with femoropopliteal intermittent claudication who received percutaneous transluminal angioplasty (PTA) with a DEB S.

The primary endpoint (PEP) was primary patency, defined as restenosis (peak systolic velocity ≥2.5) and clinically driven target lesion revascularization.

The mean patient age was 74 years, and most subjects were men. Overall, 60% of patients had diabetes, 90% had hypertension, 7% had renal insufficiency, and 22% had suffered a stroke. 

Additionally, 97% of the patients were at Rutherford stage 2 or 3. Mean lesion length was 124 mm and the vessel diameter was 5 mm, with 23% total occlusions and 27% moderate to severe calcification.

Read also: Pacientes con antecedente de cirugía de revascularización miocárdica y un nuevo evento de SCA no ST ¿Estrategia invasiva rutinaria?

Technical success was achieved in all patients, with a procedural success rate of 96%. The residual lesion rate was 20% and 2% of patients required bailout stenting.

At 12 months, the PEP was 87.9%, and the rate for clinically driven target lesion revascularization reached 97%. The non-related mortality rate was 6.5%; there were no amputations, and researchers observed a sustained improvement in functional class and an increase in the ankle-brachial index.

Conclusion

The SELUTION SFA JAPAN study showed that the new SELUTION sirolimus-eluting balloon is safe and effective for the treatment of femoropopliteal disease in symptomatic patients.

Dr. Carlos Fava - Consejo Editorial SOLACI

Dr. Carlos Fava.
Member of the Editorial Board of SOLACI.org.

Original Title: A Novel Sirolimus-Coated Balloon for the Treatment of Femoropopliteal Lesions The SELUTION SFA Japan Trial.

Reference: Osamu Iid, et al. J Am Coll Cardiol Intv 2024 Article in Press.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Transcatheter Deep Vein Arterialization in Critical Limb Ischemia Without Revascularization Options

Chronic limb-threatening ischemia in patients without conventional revascularization options represents one of the most challenging scenarios within peripheral arterial disease, with 1-year major amputation...

Duration of Smoking Cessation and Risk of Amputation After Revascularization in Critical Limb Ischemia

Critical limb ischemia (CLI) is associated with high rates of amputation and mortality. Although smoking cessation improves outcomes after revascularization, the impact of the...

Conservative management of endoleaks in complex aortic endografts under CT angiography follow-up

Endoleaks remain one of the leading causes of reintervention after endovascular repair of complex aortic aneurysms using fenestrated and/or branched endografts (F/B-EVAR). Traditionally, type...

Is upper-limb aerobic training an effective alternative to lower-limb exercise in peripheral artery disease?

Peripheral artery disease is associated with impaired functional capacity, reduced walking distance, and poorer quality of life, and structured exercise is a class I...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Transcatheter Deep Vein Arterialization in Critical Limb Ischemia Without Revascularization Options

Chronic limb-threatening ischemia in patients without conventional revascularization options represents one of the most challenging scenarios within peripheral arterial disease, with 1-year major amputation...

Transcatheter Paravalvular Leak Closure: Mid-Term Outcomes and Prognostic Factors

Paravalvular leaks (PVL) are a frequent complication following surgical valve replacement, occurring in 5% to 18% of prosthetic valves. Incidence varies according to valve...

After a Major Bleeding Event in Atrial Fibrillation: When Should Left Atrial Appendage Closure Be Considered?

Atrial fibrillation (AF) in patients who experience a major bleeding event represents a complex clinical scenario in which percutaneous left atrial appendage closure (LAAC)...